Everolimus
- TRADE NAMES: Afinitor (Novartis); Certican (Novartis); Zortress (Novartis)
- INDICATIONS: Prophylaxis of organ rejection in adults following kidney or liver transplant; advanced renal cell carcinoma; neuroendocrine tumors of pancreatic, gastrointestinal or lung origin; breast cancer in post-menopausal women with advanced hormone-receptor positive, HER2-negative type cancer; renal angiomyolipoma and tuberous sclerosis complex; subependymal giant cell astrocytoma associated with tuberous sclerosis
- CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Immunosuppressant, mTOR inhibitor
- HALF-LIFE: ~30 hours
Aprepitant, Atazanavir, Atorvastatin, Benazepril, Captopril, Clarithromycin, Clozapine, Conivaptan, Cyclosporine, Darunavir, Delavirdine, Digoxin, Efavirenz, Enalapril, Erythromycin, Grapefruit Juice, Indinavir, Itraconazole, Ketoconazole, Lapatinib, Lisinopril, Live vaccines, Nelfinavir, Oxcarbazepine, Phenytoin, Posaconazole, Quinapril, Ramipril, Ribociclib, Rifampin, Rifapentine, Ritonavir, Saquinavir, St John's Wort, Telithromycin, Venetoclax, Verapamil, Viloxazine, Voriconazole
PREGNANCY CATEGORY: D
In immunosuppression therapy: MALIGNANCIES AND SERIOUS INFECTIONS, KIDNEY GRAFT THROMBOSIS; NEPHROTOXICITY
In heart transplantation: MORTALITY
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of everolimus in kidney transplantation in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 01/27/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
